Article Search

Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts

July 1, 2025

The article demonstrates that multi-omics research in tumor immunotherapy has grown rapidly since 2019, with China leading in publication volume but showing limited international collaboration. Early research focused on immune checkpoint blockade, while recent trends emphasize machine learning, multi-omics integration, and lncRNA, reflecting a shift toward predictive modeling and biomarker discovery. Multi-omics approaches have enabled the development of immune infiltration-based prognostic models and identified metabolic and spatial biomarkers, such as oxidative phosphorylation in melanoma and ENPP1 in Ewing sarcoma, which may guide therapeutic strategies. Overall, the study provides a systematic framework for tracking technological convergence and emerging frontiers, highlighting the need for longitudinal omics monitoring, AI-driven integration, and enhanced international collaboration to optimize precision-driven tumor immunotherapy.

Read More »

Uterine leiomyosarcoma

July 1, 2025

Shout out to Dr. Monk who is the first author on this study!
Uterine leiomyosarcoma (uLMS) is a rare, aggressive uterine malignancy with a 5-year OS ranging from 51–76% in FIGO stage I to just 10–15% in stage IV, and a median OS of 10 months for advanced disease. The mainstay of treatment for localized disease is en-bloc TH ± BSO, with observation recommended postoperatively for stage I; adjuvant chemo or RT has not shown a clear survival benefit in early-stage disease. For advanced or unresectable cases, doxorubicin-based regimens (± trabectedin) remain standard, but even with multimodal therapy, outcomes remain poor (5-year recurrence 40–75%, 70% distant). Novel strategies—anti-angiogenics, ICIs, PARP inhibitors—are under investigation, but robust data are lacking. Bottom line: uLMS continues to challenge us with its aggressive biology and limited therapeutic gains, so we need to keep pushing for trial enrollment and molecularly targeted approaches.

Read More »

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

June 1, 2025

There is no standard therapy for this type of cancer, which could be sporadic or associated with germline mutations (Hereditary leiomyomatosis and renal-cell cancer) in HLRCC-associated papillary renal-cell carcinoma. Responses were observed in 72%, the median progression-free survival was 21.1 months, and the median overall survival was 44.6 months. In sporadic papillary renal-cell carcinoma 35% had responded with a median progression-free survival of 8.9 months, median overall survival of 18.2 months. This is a promising combination.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts